色谱Issue(3)：290-293,4.DOI:10.3724/SP.J.1123.2013.11027
高效液相色谱-串联质谱法测定比格犬血浆中的莫诺苷浓度及其药代动力学
Determination of morroniside concentration in beagle plasma and its pharmacokinetics by high performance liquid chromatography-tandem mass spectrometry
摘要
Abstract
A sensitive,simple and specific high performance liquid chromatography-electros-pray ionization tandem mass spectrometry( LC-MS / MS)method was developed for the deter-mination of morroniside in the plasma of beagles administered via intragastric( ig)doses of morroniside. The method employed paeoniflorin as the internal standard and extracted by sim-ple protein precipitation. The separation was achieved using an Inertsil ODS-SP column(50 mm ×2. 1 mm,5 μm)with mobile phases of 1 mmol / L sodium formate aqueous solution and aceto-nitrile(gradient elution)at a flow rate of 0. 4 mL / min. The detection was accomplished by a mass spectrometer using multiple reaction monitoring( MRM)in positive mode. Pharmacoki-netic parameters were fitted by software DAS 2. 0. The methodological study showed a good lin-ear relationship of 2-5 000 μg / L(r = 0. 996 6)with a sensitivity of 2 μg / L as the limit of quanti-fication. The precision,accuracy,mean recoveries and the matrix effects were satisfied with the requirements of biological sample measurement. The method described above was success-fully applied to the pharmacokinetic study of morroniside in the beagle plasma samples. The area under the plasma concentration-time curves( AUC( 0-∞ )) of morroniside after single ig administration doses of 5,15 and 45 mg / kg were(1 631. 20±238. 50),(3 984. 05±750. 38)and (10 397. 64±3 156. 34)μg / L·h. The relationship between dose and AUC showed a good linearity. The pharmacokinetic property of morroniside was proposed to be linear pharmacokinetics.关键词
液相色谱-串联质谱/莫诺苷/血浆/比格犬/药代动力学Key words
liquid chromatography-tandem mass spectrometry ( LC-MS / MS )/morroniside/plasma/beagle/pharmacokinetics分类
化学化工引用本文复制引用
熊山,李敬来,朱秀清,王晓英,吕圭源,张振清..高效液相色谱-串联质谱法测定比格犬血浆中的莫诺苷浓度及其药代动力学[J].色谱,2014,(3):290-293,4.基金项目
科技部“重大新药创制”科技重大专项（2012ZX09301003-001-007）． （）
